Cartesian Therapeutics Inc (NAS:RNAC)
$ 17.91 -0.74 (-3.97%) Market Cap: 455.18 Mil Enterprise Value: 250.63 Mil PE Ratio: 0 PB Ratio: 577.74 GF Score: 56/100

Q2 2023 Selecta Biosciences Inc Earnings Call Transcript

Aug 17, 2023 / 12:30PM GMT
Release Date Price: $33.6 (+2.75%)
Operator

Good morning, everyone, and thank you for joining the Selecta Biosciences Q2 2023 Earnings Call. (Operator Instructions) At this time, I'd like to turn the floor over to Blaine Davis, Chief Financial Officer of Selecta. Please go ahead.

Blaine T. Davis
Selecta Biosciences, Inc. - CFO

Good morning, everyone, and thank you for joining our second quarter 2023 financial results and business update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website at www.selectabio.com and in our quarterly report on Form 10-Q for the quarter ended June 30, 2023, which was filed earlier this morning with the Securities and Exchange Commission. Joining me on today's call are Selecta's President and Chief Executive Officer, Dr. Carsten Brunn; and Peter Traber, our Chief Medical Officer.

During today's call, we will be making certain forward-looking statements, including without limitation, statements about the potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot